A growing body of scientific evidence supports the use of NfL as a prognostic biomarker in the broad ALS population, and a risk/susceptibility biomarker among a subset of SOD1 pathogenic variant carriers [4]. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.